Moreover, germline BRCA carriers had worse outcomes than noncarriers when conventionally treated with surgery or radiation therapy for local/locally advanced PCa [29]. Additional studies found that BRCA2 germline carriers were strongly associated with rapidly progressing lethal prostate cancer [30] and poor survival [31,32]. Here, BRCA2 is linked to prostate carcinoma.